January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Karen Knudsen: More of technology meeting healthcare
Jan 7, 2025, 11:32

Karen Knudsen: More of technology meeting healthcare

Karen Knudsen, Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS), shared a post on LinkedIn:

“Here we go– more of technology meeting healthcare! A new international study revealed the potential for great strides in ovarian cancer detection, wherein AI models showed superior performance compared to both expert and non-expert evaluations using ultrasound.

The impact could be profound, as there is no validated screening tool for ovarian cancer, experts in ultrasound detection are globally in short supply, and many ovarian cancer cases are diagnosed at later stages when treatment options are less effective.

Notable in the study by Christiansen et al. was that the AI model achieved high accuracy, sensitivity, and specificity, underscoring the potential to assist in earlier and more accurate diagnoses. If correct, this is a way to complement medical expertise and enhance diagnostic precision, particularly for cancers where early detection is crucial. Next up… prospective studies?”

Karen Knudsen: More of technology meeting healthcare

International multicenter validation of AI-driven ultrasound detection of ovarian cancer

Authors: Filip Christiansen et al.

Karen Knudsen: More of technology meeting healthcare

Karen E. Knudsen is the Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health.

She also served as president for the Association of American Cancer Institutes (AACI) and on the board of directors of the American Association for Cancer Research (AACR). She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers.

She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.